Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.45 |
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | GABRE | P78334 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.45 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.45 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urea SCHEMBL4201729 | 0.94 | POLB (0.43) | POLBGABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL15082266 | 0.89 | TSHR (0.38) | POLBGABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL21235945 | 0.89 | TSHR (0.38) | POLBGABRA1TSHRGABRG2GABRB3 | |
| Trifluoroacetic Acid SCHEMBL28974434 | 0.88 | GABRA1 (0.40) | POLBGABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL4110765 | 0.85 | POLB (0.36) | POLBTSHRKMT2ALMNAALDH1A1 | |
| SCHEMBL7695741 | 0.81 | HDAC8 (0.48) | TSHRLMNAALDH1A1SMN1; SMN2EPHX1 | |
| SCHEMBL15931748 | 0.81 | HDAC8 (0.43) | TSHRLMNAALDH1A1SMN1; SMN2EPHX1 | |
| SCHEMBL17294409 | 0.79 | CHRNB2 (0.39) | NOS2 | |
| SCHEMBL19060 | 0.79 | HDAC8 (0.52) | TSHRALDH1A1SMN1; SMN2EPHX1 | |
| SCHEMBL30803944 | 0.78 | SLC6A1 (0.52) | TSHRCYP2D6KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111601804-B | Nitrogen-containing heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-115232109-A | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 广东东阳光药业有限公司 | 2022-10-25 | — | — | CN | disclosed |
| WO-2021110076-A1 | OXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 深圳信立泰药业股份有限公司 | 2021-06-10 | — | — | WO | disclosed |
| EP-3478680-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | HOFFMANN LA ROCHE (CH) | 2020-04-22 | — | — | EP | disclosed |
| US-20190241559-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-08-08 | — | — | US | disclosed |
| CN-104619709-B | Imidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-11-09 | — | — | CN | disclosed |
| EP-2029539-B1 | N-(piperidinyl)-urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of e.g. hypertension or inflammations | UNIV CALIFORNIA (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-9029550-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080221105-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080207908-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | ARETE THERAPEUTICS, INC | 2008-08-28 | — | — | US | disclosed |
| WO-2008094862-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | ARETE THERAPEUTICS, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008094869-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-27 | — | — | US | disclosed |
| WO-2007106525-A1 | PIPERIDINYL, INDOLYL, PIRINIDYL, MORPHOLINYL AND BENZIMIDAZOLYL UREA DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE FOR THE TREATMENT OF HYPERTENSION, INFLAMMATIONS AND OTHER DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-1322596-B1 | ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-08-15 | — | — | EP | disclosed |
| US-6479518-B2 | PSYCHOLOGICAL DISORDERS | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | MERCK & CO., INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | NPY5R, NPY1R, NPY2R | POLB 4866/4885GABRA1 360/4885TSHR 241/4885 |
| US-20190241559-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | TYMP, RECQL, DPYD | POLB 178/4885GABRA1 3057/4885TSHR 2416/4885 |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | POLB 2136/4885GABRA1 2915/4885TSHR 3335/4885 |
| US-20080221105-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | EPHX1, NCEH1, PNLIP | POLB 2388/4885GABRA1 2682/4885TSHR 2459/4885 |
| US-20080207908-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | UMPS, CPS1, NISCH | POLB 101/4885GABRA1 2683/4885TSHR 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.